MYC and hepatocellular carcinoma: Now that we have proved CU27 can sensitize Dox, 5‐FU, and sorafenib in HCC cells, we further aim to test the synergistic therapeutic effect of CU27 and sorafenib in a metastatic mouse model using HCCLM3 cells, which are characterized by a high c‐Myc expression level and a high metastatic potential, as we previously reported.[26, 38, 39] Visible tumor nodules appeared in all the groups (Figure 7A; Figure S8, Supporting Information).